Filing Overview
This Form 6-K was filed on March 4, 2022, by I-MAB, a foreign private issuer headquartered in Shanghai, China, for the month of March 2022. The filing identifies I-MAB as the registrant; the provided company metadata refers to Novabridge Biosciences, which does not match the filing.
Financial and Operating Information
The filing contains only the Form 6-K cover page and an exhibit index. It does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes and Outlook
The filing references Exhibit 99.1, described as a press release, but the press release text is not included in the provided filing content. Accordingly, the filing text does not provide clear information regarding material changes, guidance, management commentary, risks, contingencies, or unusual items.
Investor Verification Items
- Verify the issuer identity, because the filing names I-MAB rather than Novabridge Biosciences.
- Obtain and review Exhibit 99.1, the referenced press release, for the substantive disclosure.
- Confirm whether the press release contains financial results, clinical or business developments, guidance, risk factors, or other material information.
- Review I-MAB’s related Form 20-F and subsequent filings for complete financial and operating information.